SCHEMBL3236567

SCHEMBL3236567

Fc1ccc(Cc2cccs2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.53
SMN1; SMN2 Q16637 4/20 0.51
RAB9A P51151 3/20 0.51
TP53 P04637 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
POLB P06746 3/20 0.50
SLC6A3 Q01959 1/20 0.47
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
DRD4 P21917 1/20 0.46
DRD5 P21918 1/20 0.46
ABL1 P00519 1/20 0.46
LMNA P02545 2/20 0.45
KCNH3 Q9ULD8 1/20 0.44
TAAR1 Q96RJ0 1/20 0.42
RECQL P46063 1/20 0.42
NPC1 O15118 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28817472 0.82 PTGS1 (0.46) HPGDSMN1; SMN2RAB9AL3MBTL1POLB
SCHEMBL45228 0.80 LMNA (0.50) HPGDSMN1; SMN2RAB9AL3MBTL1POLB
SCHEMBL6076332 0.80 LTA4H (0.44) RAB9AL3MBTL1POLBPTGS1PTGS2
SCHEMBL10525378 0.79 L3MBTL1 (0.55) L3MBTL1PTGS1PTGS2DRD4LMNA
SCHEMBL20738474 0.79 MEN1 (0.61) HPGDSMN1; SMN2RAB9ATP53POLB
SCHEMBL3238290 0.79 LMNA (0.62) HPGDSMN1; SMN2L3MBTL1POLBSLC6A3
SCHEMBL7294757 0.79 CYP3A4 (0.52) HPGDL3MBTL1POLBPTGS1PTGS2
SCHEMBL10953000 0.79 HPGD (0.46) HPGDPOLBPTGS1PTGS2LMNA
SCHEMBL11660485 0.79 TAAR1 (0.42) L3MBTL1PTGS1PTGS2LMNATAAR1
SCHEMBL3385419 0.79 MEN1 (0.54) HPGDSMN1; SMN2RAB9ATP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119876994-A Copper-based electrocatalytic material and preparation method and application thereof 中国石油化工股份有限公司 2025-04-25 CN claimed
CN-119096372-A Photovoltaic device and method of manufacture 第一阳光公司 2024-12-06 CN claimed
CN-116918029-A selective thermal atomic layer deposition 弗萨姆材料美国有限责任公司 2023-10-20 CN claimed
CN-116761906-A Selective plasma enhanced atomic layer deposition 弗萨姆材料美国有限责任公司 2023-09-15 CN claimed
CN-116583623-A Selective deposition of silicon and oxygen containing dielectric films on dielectrics 弗萨姆材料美国有限责任公司 2023-08-11 CN claimed
CN-110192294-B Lithium electrode and lithium secondary battery comprising same 株式会社LG新能源 2022-09-20 CN claimed
CN-111033864-B Electrolyte for lithium metal battery and lithium metal battery comprising same 株式会社LG新能源 2022-08-12 CN claimed
US-20070117775-A1 Compositions and Methods For Treating Inflammatory Disorders RIGEL PHARMACEUTICALS, INC. (US) 2007-05-24 US claimed
EP-0719771-A1 Process for the preparation of methylene compounds and the compound 2-(2',4'-dichloro-5'-fluorobenzyl)-thiophene BAYER AG (DE) 1996-07-03 EP claimed
CN-120201999-A Antimicrobial compositions AHV国际有限公司 2025-06-24 CN disclosed
CN-115724882-B Phosphorothioates method for synthesizing compound 南通大学 2025-05-27 CN disclosed
CN-119096372-A Photovoltaic device and method of manufacture 第一阳光公司 2024-12-06 CN disclosed
CN-117466790-B Preparation method of alpha-sulfinylated carbonyl compound 西北师范大学 2024-05-28 CN disclosed
CN-114945627-B Cation-exchange and anion-exchange polymers and blend membranes prepared from fluorinated aromatic group-containing polymers by nucleophilic substitution 斯图加特大学 2024-05-24 CN disclosed
EP-0667855-A4 SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS. ABBOTT LAB (US) 1996-02-21 EP disclosed
WO-1995030671-A1 SUBSTITUTED ARYL- AND HETEROARYLALKENYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS ABBOTT LABORATORIES (US) 1995-11-16 WO disclosed
EP-0667855-A1 SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS ABBOTT LABORATORIES (US) 1995-08-23 EP disclosed
WO-1995012589-A1 PROCESS FOR THE PREPARATION OF N-4-[(SUBSTITUTED PHENYL)ALKYLTHIENYL]-, AND N-4-[(SUBSTITUTED PHENYL)ALKYLFURYL]BUT-3-YN-2-YL]-N-HYDROXYUREA COMPOUNDS ABBOTT LABORATORIES (US) 1995-05-11 WO disclosed
WO-1994011342-A1 SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS ABBOTT LABORATORIES (US) 1994-05-26 WO disclosed
US-5288751-A [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis ABBOTT LABORATORIES (US) 1994-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117775-A1 Compositions and Methods For Treating Inflammatory Disorders SYK, IRAK2, IRAK4 HPGD 1967/4885SMN1; SMN2 2396/4885RAB9A 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.